Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Accord Innovates With Cancer Support App

Accord Healthcare has launched an app to support cancer patients and help manage symptoms, incorporating expert data from Macmillan Cancer Support.

Value-Added Medicines Cancer

Amneal Targets Migraine With 505(b)(2) Filing

Amneal is setting its sights on the migraine and cluster headache market in the US with a new hybrid 505(b)(2) filing for a dihydroergotamine autoinjector.

Value-Added Medicines Strategy

Less Than Two Months Remain To Enter Global Generics & Biosimilars Awards 2021

With a looming entry deadline of 30 July, companies have a little under two months to enter the Global Generics & Biosimilars Awards 2021, ahead of the awards ceremony on 10 November.

Generic Drugs Biosimilars

Zentiva Invests €27m In Prague Plant

Zentiva has announced that it is investing a further €27m in expanding its flagship manufacturing plant in Prague, having already pumped €35m into the site over the past three years.

Manufacturing Strategy

Eagle Has Japanese Nod For New Bendamustine Indication

Eagle Pharmaceuticals has received approval for a new indication in Japan for its Treakisym (bendamustine) used to diffuse large B-cell lymphoma. The company is looking to expand as it expects the new indication to generate an opportunity worth up to $25m.

Value-Added Medicines Strategy

Hyloris Pushes Into South America With Maxigesic IV

Hyloris is on a roll with licensing deals for its Maxigesic IV non-opioid pain treatment, with an extension of its existing agreement with Pharma Bavaria to cover South American territories coming hot on the heels of recent developments in the US and Europe.

Deals Value-Added Medicines
See All
UsernamePublicRestriction

Register